Skip to content
Sign in
StableHealthReported 2026-11-10 06:28

FDA approves Bayer drug Sunharbo to reduce stroke recurrence

The FDA approved Bayer's Sunharbo, a novel XIa inhibitor, as the first medication in its class to reduce stroke recurrence. In a Phase 3 trial, Sunharbo reduced the risk of secondary stroke by 26% compared to placebo, with 53 patients needing treatment over one year to prevent one recurrence, offering a safer alternative to traditional blood thinners.

Why it matters. Provides a new treatment option that could prevent secondary strokes more safely for patients who cannot tolerate existing blood thinners due bleeding risk, potentially improving stroke outcomes globally.

01

Who and what it touches

Phylo, Inc.servesMonsantoacquiresBiomni LabusesPancreatic Cancer Mar…operates inRoundupmanufacturesAmazonsuppliesMyerstown, Pennsylvan…located inOhio pharmaceutical f…invests inBayer

Into Bayer

From Bayer

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • SSTATMedia2026-11-10 06:28
    View source
  • BBioPharma DiveMedia2026-11-10 06:40
    View source